Hims & Hers’ earnings soar while GLP-1 drug crisis deepens—what this means for investors
Hims & Hers Health Inc. saw its stock surge following a robust quarterly earnings report, which showcased significant growth in revenue and subscriber numbers. Despite ... Read More
Novo Nordisk stock climbs 1.52% as obesity drug Liraglutide shows promise in young kids
Novo Nordisk A/S shares climbed by 1.52% today to 888.60 DKK, following the release of promising new data on its obesity drug Liraglutide, which has ... Read More
Biocon and Juno Pharmaceuticals ink game-changing diabetes drug deal
Biocon Limited, the innovation-driven global biopharmaceutical frontrunner, has made headlines by sealing a significant partnership agreement with Juno Pharmaceuticals, Canada's esteemed specialty pharmaceutical giant. This ... Read More
Biocon partners with Zentiva for European marketing of Liraglutide
Biocon Limited has entered into a semi-exclusive partnership with Zentiva, a Czech pharma company for marketing its drug-device combination Liraglutide for the treatment and management ... Read More
Novo Nordisk gets Saxenda FDA updated label to cover obesity treatment in adolescents
Novo Nordisk has been given approval from the US Food and Drug Administration (FDA) for an updated label for Saxenda (liraglutide) injection 3 mg for ... Read More
Scientists identify drug for obese people to lose weight by reducing appetite
Good news for all the obese people who want to lose weight as scientists found a new drug that could help genetically obese persons to ... Read More